These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 15577030)

  • 1. [K/DOQI clinical practice guidelines for management of renal osteodystrophy in predialysis patients].
    Okada N; Tsubakihara Y
    Clin Calcium; 2004 May; 14(5):698-706. PubMed ID: 15577030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of metabolic bone disease in the pre-end-stage renal disease setting.
    Coburn JW; Elangovan L
    J Am Soc Nephrol; 1998 Dec; 9(12 Suppl):S71-7. PubMed ID: 11443772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Vitamin D therapy in predialysis renal failure].
    Ando R
    Clin Calcium; 2004 Sep; 14(9):73-7. PubMed ID: 15577115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical evidence and treatment for optimum concentration of parathyroid hormone, calcium and phosphate in chronic renal failure].
    Hoshino J; Ubara Y; Takaichi K
    Clin Calcium; 2004 May; 14(5):731-7. PubMed ID: 15577034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges in the therapy of secondary hyperparathyroidism.
    Wood C; González EA; Martin KJ
    Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consequences of the implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease in a population of patients on chronic hemodialysis.
    Arenas MD; Alvarez-Ude F; Torregrosa V; Gil MT; Carretón MA; Moledous A; Nuñez C; Devesa R; Albiach B
    J Nephrol; 2007; 20(4):453-61. PubMed ID: 17879212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of bone mineral metabolism in patients with stage 3-5 chronic kidney disease not on dialysis: results of the OSERCE study.
    Górriz JL; Molina P; Bover J; Barril G; Martín-de Francisco AL; Caravaca F; Hervás J; Piñera C; Escudero V; Molinero LM;
    Nefrologia; 2013 Jan; 33(1):46-60. PubMed ID: 23364626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.
    Zisman AL; Hristova M; Ho LT; Sprague SM
    Am J Nephrol; 2007; 27(1):36-43. PubMed ID: 17215573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The medical treatment strategy of secondary hyperparathyroidism use of vitamin D in Europe and America].
    Miwa N; Akiba T
    Clin Calcium; 2004 Sep; 14(9):57-9. PubMed ID: 15577111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Secondary hyperparathyroidism and tertiary hyperparathyroidism chronic renal failure, uremia].
    Morio K; Koide K
    Nihon Rinsho; 1995 Apr; 53(4):958-64. PubMed ID: 7752492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure.
    Rix M; Andreassen H; Eskildsen P; Langdahl B; Olgaard K
    Kidney Int; 1999 Sep; 56(3):1084-93. PubMed ID: 10469378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low.
    Ennis JL; Worcester EM; Coe FL; Sprague SM
    J Nephrol; 2016 Feb; 29(1):63-70. PubMed ID: 25736620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parathyroid hormone and biochemical profile in chronic kidney disease patients in South India.
    Sankarasubbaiyan S; Abraham G; Soundararajan P; Chandrasekaran V; Padma G
    Hemodial Int; 2005 Jan; 9(1):63-7. PubMed ID: 16191055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
    Shahapuni I; Mansour J; Harbouche L; Maouad B; Benyahia M; Rahmouni K; Oprisiu R; Bonne JF; Monge M; El Esper N; Presne C; Moriniere P; Choukroun G; Fournier A
    Semin Dial; 2005; 18(3):226-38. PubMed ID: 15934970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guideline-practice gap in the management of predialysis chronic kidney disease mineral bone disorder in Japan.
    Hamano T; Fujii N; Matsui I; Nakano C; Inoue K; Tomida K; Mikami S; Okada N; Tsubakihara Y; Rakugi H; Isaka Y
    Ther Apher Dial; 2011 Jun; 15 Suppl 1():2-8. PubMed ID: 21595844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Guideline for the management of chronic kidney disease-related mineral and bone disorders (CKD-MBD)].
    Kakuta T
    Clin Calcium; 2007 May; 17(5):752-9. PubMed ID: 17471006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.